MEDICAL ALERT: Pills Recalled Over ‘Superpotent’ Danger

One lot of thyroid tablets was pulled nationwide after tests showed the pills could deliver too much hormone.

Story Snapshot

Vitruvias recalled one lot of 30 mg thyroid tablets at the consumer level.
Tests showed the potential for “superpotent” pills that can trigger hyperthyroidism.
A total of 3,655 units were released; 1,955 were sold across the United States.
No related adverse events have been reported to date, the company said.

What Was Recalled, When, and Why It Matters

Vitruvias Therapeutics announced a nationwide recall of one lot of Thyroid Tablets, United States Pharmacopeia 30 milligrams, after testing showed the potential for superpotency. The recall covers Lot 504950, with National Drug Code 69680-166-00, and an expiration date of September 30, 2026.

The company initiated the recall at the consumer level, which means patients should check their bottles and stop using the affected lot. Thyroid hormone has a tight dosing window, so even modest overstrength can push patients into hyperthyroidism.

'Superpotent' Thyroid medication recalled one month after FDA advises against similar tablets https://t.co/jGK75IOEcX pic.twitter.com/jhFrWTCro8

— New York Post (@nypost) August 25, 2026

The Food and Drug Administration notice describes the clinical risks from excess thyroid hormone. Symptoms can include weight loss, heat intolerance, fatigue, nervousness, muscle weakness, high blood pressure, chest pain, rapid heart rate, or heart rhythm problems.

These effects can strain the heart, especially in older adults, and in people with existing heart disease. The fastest safe action is to stop the recalled lot and contact a pharmacist or doctor for guidance on a replacement.

Scope of Distribution and How Many Bottles Are Out There

The recall involves a narrow slice of supply, but it reached nationwide distribution through direct accounts. The company reports 3,655 units were released and 1,955 were sold between January 31, 2025, and September 30, 2025.

Pharmacies, clinics, and mail-order channels may still have stock. Patients who use 30 milligram thyroid tablets should check the bottle’s lot number and National Drug Code against the recall. When in doubt, ask the dispensing pharmacy to confirm.

Vitruvias reports no adverse events tied to this lot as of the notice date. That detail suggests the recall is precautionary and lab-driven, not injury-driven. That is how the system should work.

Quality testing is supposed to catch issues before patients get hurt. The recall also aligns with past thyroid-drug potency actions, where even single-digit percent swings in dose can matter due to the narrow therapeutic window.

What To Do If You Have The Affected Lot

Stop using any bottle that matches Lot 504950 and National Drug Code 69680-166-00. Call your pharmacist to arrange a replacement and return. Bring the bottle, since the lot and code are on the label.

If you feel racing heart, chest pain, or new severe symptoms, seek care right away. Doctors may order a thyroid blood test to check your levels. Keep a list of your symptoms and when they started. That helps your clinician make a faster, safer plan.

Recall: Vitruvias Thyroid Tablets USP 30 mg — lot 504950, exp. 9/30/2026, NDC 69680-166-00 — for potential superpotency.

Check your bottle. If it matches, contact your pharmacy or clinician. Do not discontinue without clinician guidance.https://t.co/rRHBYf0Ump

— The Modern Bio (@themodernbio) August 26, 2026

Patients should not make dose cuts or skip pills without talking to their prescriber. Thyroid dosing changes ripple through the body over days to weeks. A planned switch to a non-recalled lot or strength keeps levels steady.

Keep in mind, most thyroid tablets on the market are not part of this recall. The notice covers only one lot of one strength. If your bottle’s lot number and National Drug Code do not match, continue your usual dose unless your doctor advises a change.

Why Thyroid Recalls Happen More Than You Think

Thyroid hormone drugs sit in a clinical tightrope zone. Too little leads to fatigue, weight gain, and fog. Too much speeds the heart and strains the body.

That is why potency errors are a known recall category in the Food and Drug Administration data set and why thyroid products see more headlines than many other generics when quality flags appear. These recalls show the quality system doing its job: test, detect, notify, correct—before harm becomes the story.